David James Kerr

CBE, MA (Oxon), MBChB, BSc (Hons), MSc, PhD, MD, DSc, FRCP (Glasgow,Edinburgh and London), FRCGP (hon), FCanSci, FMedSci

CURRICULUM VITAE

Professor of Cancer Medicine, University of Oxford

Adjunct Professor of Medicine, Weill Cornell Medical College, New York

Past President, European Society of Medical Oncology

1

CONTENTS

EDUCATION.................................................................................................................... 4

POSTGRADUATE FELLOWSHIPS AND PRIZES..................................................................5

MEDICAL ONCOLOGY CAREER........................................................................................6

CURRENT APPOINTMENTS..............................................................................................7

MEMBERSHIP OF SOCIETIES...........................................................................................7

CLINICAL AND SCIENTIFIC LEADERSHIP........................................................................10

CLINICAL DUTIES..........................................................................................................10

TRANSLATIONAL CANCER RESEARCH: GENE THERAPY OF CANCER.............................10

INTERACTION WITH INDUSTRY.....................................................................................11

INTERNATIONAL COLLABORATIONS:.............................................................................11

ORGANISATIONAL LEADERSHIP....................................................................................12

RESEARCH GRANTS RECEIVED.....................................................................................14

PUBLICATIONS..............................................................................................................18

PUBLISHED ABSTRACTS................................................................................................18

THESES......................................................................................................................... 18

PEER REVIEWED PUBLICATIONS...................................................................................19

PUBLISHED BOOK CHAPTERS.......................................................................................40

EDITED BOOKS.............................................................................................................42

JOURNAL EDITORIAL BOARDS.......................................................................................42

2

EDUCATION

University of Glasgow

Medical degreesMBChB 1980

MD Aspects of Cytotoxic Drug Penetration 1987

Science degrees

MA

2002

University of Oxford

HONOURS and FELLOWSHIPSElected Fellow of Royal College of Physicians and Surgeons, Glasgow (FRCP, Glas)

Elected Fellow of Royal College of Physicians, London (FRCP, Lon) Elected Fellow of Academy of Medical Sciences (FMed Sci)

Awarded Commander of Order of British Empire, by HM the Queen (CBE)

1995

1996

2000

2002

Elected Honorary Fellow of Royal College of General Practitioners (FRCGP)

2007

Elected Founding Fellow of European Academy of Cancer Sciences (FCanSci)

2009

Elected Fellow of Royal College of Physicians, Edinburgh (FRCP, Edin)

2010

3

BSc First class honours in Biochemistry 1977

MSc in Clinical Pharmacology 1990

PhD Regulation of proliferation of breast cancer cells by growth factors 1990

DSc The molecular and clinical pharmacology of anticancer therapy 1996

POSTGRADUATE FELLOWSHIPS AND PRIZES

Graham Wilson Travelling Fellow 1985

Jean M MacKintosh Research Fellowship 1985

Visiting Scientist, Chronobiology Laboratories, University of Minnesota, Minneapolis, USA

1986

Cancer Research Campaign Travel Fellowship 1986

Graham Wilson Travelling Fellow 1986

Travelling Fellowship from National Cancer Institute to attend laboratories of Dr M Lippman and Dr M Sporn

1987

Travelling Fellowship Royal College of Physicians and Surgeons, Glasgow 1987

Alexander Fletcher Memorial Prize, Royal College of Physicians and Surgeons for distinguished research into thyroid cancer

1987

European School of Oncology International Award for outstanding contribution to chemotherapy research

1987

Graham Wilson Travelling Fellow, University of Glasgow 1988

British Association for Cancer Research Fellowship 1988

International Union against Cancer - Cancer Research Fellowship International Cancer Research Exchange Technology Transfer Grant

1989

May and Baker Prize for essay on Aspects of Therapy Royal College of Physicians & Surgeons, Glasgow

1991

Pauline TSU Memorial Lecture, Royal College of Physicians & Surgeons, Edinburgh 1992

International Society of Geriatrics - Zeneca Lecture "Treatment of cancer in the elderly"

1995

Royal Society of Art Annual Lecture 1995

10th Erasmus Darwin Lecture 1996

2nd International Prize for Excellence in the field of Colorectal Cancer Research and Treatment – Awarded by International Drug Development Centre and European Association for Research into Gastrointestinal Cancer

1999

1st Nye Bevan Award for Innovation – Awarded by NHS for Gene Therapy Research

AstraZeneca: Oncology and Infections Vision and Values Award

2000

2005

Distinguished Medeval Lecture, University of Manchester 2006

4

European Society of Medical Oncology Award for distinguished contribution to Cancer therapy and research in Europe

2006

Fulton Lecture, University of Glasgow 2007

Bruce Cain Memorial Lecture, Cancer Societies of Australia and New Zealand 2008

5

MEDICAL ONCOLOGY CAREER

University of Glasgow

Prof S B Kaye CRC Dept of Medical Oncology,CRC Research Fellow (Honorary Registrar)

April 1984 - September 1986

Beatson Institute for Cancer Research, Honorary Senior Registrar

October 1986 - September 1988

MRC Recombinant DNA Training Fellowship

CRC Senior Research Fellow, Hon Senior Registrar

October 1988 - June 1989

CRC Senior Fellow, Senior Lecturer in MedicalOncology and Honorary Consultant Physician and Pharmacology Group LeaderCRC Dept of Medical Oncology,

July 1989 - February 1992

Honorary Professor of Pharmacology, University of Strathclyde

July 1990 – present

University of Birmingham

Professor of Clinical Oncology and Clinical Director, CRC Institute for Cancer Studies,

March 1992 – 2001

Honorary Consultant Physician, Birmingham Oncology Centre,Queen Elizabeth and City Hospitals

March 1992 – 2001

University of Oxford

Director, National Translational Cancer Research Network

October 2001 – April 2006

Rhodes Professor of Cancer Therapeutics and Clinical Pharmacology;

Head of Department Clinical Pharmacology;

Fellow, Corpus Christi College , Oxford;

Honorary Consultant in Medical Oncology -

October 2001 – March 2009

6

Radcliffe Hospital Trusts

7

Sidra Medical and Research Centre, Doha, Qatar (leave of absence from Oxford)

Chief Research Advisor

Member, Supreme Health Council, State of Qatar

Professor of Cancer Medicine, University of Oxford

Adjunct Professor of Medicine, Weill Cornell Medical College

Honorary Consultant in Medical Oncology – Al Amal Hospital, Doha

Professor of Cancer Medicine,Nuffield Dept of Clinical and Laboratory Sciences, 2010 - present

Seconded as Health Adviser to Sec State for Health ,UK October, 2010 – August, 2012

Adjunct Professor of Medicine, Weill Cornell Medical College, 2009 - present

President, European Soc Medical Oncology, 2009 – 11

Chief Medical officer, Oxford Cancer Biomarkers, 2011 - present

March 2009 – October 2010

October, 2010 - current

MEMBERSHIP OF SOCIETIES

British Oncology Association British Association for Cancer Research European Society of Medical Oncology Association of Cancer Physicians

8

European Association for Cancer Research American Association for Cancer Research American Society for Clinical Oncology

9

MEMBERSHIP OF EXECUTIVE COMMITTEES

Local

University of Oxford

▪ Committee of Heads of Departments of Science, 2001-2009▪ Committee of Heads of Departments of Medical School, 2001-2009▪ Chair, Biomedical Sciences Prize Committee, 2005-2009▪ Central Committee for Estates (representing Division of Medicine), 2006-2009

National

Medical Research Council, Molecular and Cell Medicine Board, Committee A, Member (1993-1997)

Medical Research Council, Colorectal Cancer Working Party, Member - responsible for co-ordinating two international trials in advanced colorectal cancer. (1992-2003)

Medical Research Council, Clinical Fellowships Panel. (1993-1996) Medical Research Council, Realising Our Potential Awards Committee.(1995-1996) Medical Research Council, LINK with Industry Panel. (1995) Advisory Group to Commission for Health Improvement (1998) Cancer Research Campaign, Clinical Trials Committee, Member (1998-2001) Chairman, National Cancer services Collaborative (budget £30 million). (1999 – 2003) Chairman and Clinical Lead, Department of Health Audit on Cancer Waiting Times.

(1999) Founding Commissioner, Commission for Health Improvement.(1999-2001) Cancer Research Campaign, Site Visit Committee member and responsibility for

grant reports. Adviser, Commonwealth Scholarships and Fellowships (1999 – present) National Cancer Task Force, Member. (2000 – 9) Director of National Translational Cancer Research Network (2001- 2006) Chairman National Cancer Research Institute’s adjuvant colorectal cancer trials group

(2003 – 8) Member, National Colorectal Cancer Advisory Group (2003 – present) Member, Department of Health Research for Patient Benefits Working Party (2003-

2005) Chairman, National Framework for NHS in Scotland: Advisory Group (2004 – 2005)

10

International

Pan European Trial of Adjuvant Chemotherapy for Colorectal Cancer – Trial Steering Committee, UK Chairman (1995-1998)

European Society for Medical Oncology, Chairman of Scientific Committee - responsible for arranging and ensuring a high scientific content of ESMO Athens meetings (1998)

American Society for Clinical Oncology - international liaison committee of senior European and American oncologists linking ESMO and ASCO meetings (1998)

International Working Party on Colorectal Cancer: this group consists of senior academics from USA and each European Country with an interest in the treatment of colorectal cancer.(1999)

EORTC, Gastro-intestinal Study Group, Member - responsible for trans-European studies in a range of gastro-intestinal cancer. (1998 – present)

Editor-in-Chief, Annals of Oncology; scientific journal of European Society of Medical Oncology and Europe's leading clinical cancer journal. (1999 – present)

US National Institute of Health Colorectal Cancer Research Strategy Group – overseas member, 2000

Co-Chairman, Scientific Steering Committee for centenary celebration of Entente Cordiale – “Today’s Science, Tomorrow’s Patient” 2003 – 2005)

US National Cancer Institute – Translational Research Working Group (sole overseas member) 2005-2007

European Society of Medical Oncology, Presidential Cycle, 2008-2014 Chairman of INDOX – www.indox.org.uk – 2005 to date Chairman of AfrOx – www.afrox.org – 2007 – to date Member of International Scientific Advisory Board for Center for Translational

Molecular Medicine, The Netherlands – 2008 (present distribution of 500 million Euros)

Member of International Assessment Committee for Research Hospital Fund of Canadian Foundation for Innovation: distribution of $500 million, 2008

Member of Advisory Board of the Centre for Cancer Biomedicine, The Norwegian Radium Hospital, Norway, 2008 - date.

Member of Scientific Advisory Board of Institut Gustav Roussy, Paris (2009- to date) Supreme Council of Health, Qatar (2009 – 10) Chairman, OxOnics – Asia-Pacific Oncology development company (2011 – present)

11

CLINICAL AND SCIENTIFIC LEADERSHIP

Working in partnership with Professor Alan Rickinson FRS. I established the CRC Institute for Cancer Studies in University of Birmingham, built the scientific establishment from around 50-60 staff to 150-200 and secured funding to construct a new laboratory to house the expanded workforce. I supported construction of a new cancer hospital in Birmingham, forged a series of innovative clinical practices, founded clinical gene therapy in Birmingham and spun out a small biotech company, COBRA Therapeutics.

Appointment to the Rhodes Chair of Cancer Therapeutics and Clinical Pharmacology (October, 2001), University of Oxford has allowed me to work with Sir John Bell to build a new Institute for Cancer Medicine in Oxford, (£60 million) contiguous with the new cancer hospital (£125 million) on the Churchill Biomedical Campus. My recent appointed as Chief Research Advisor to the Sidra Medical and Research Centre ($3 billion build and design project) has allowed me to share the vision of Her Highness Sheikha Mozah in her desire to build a world class research environment in Doha. This represented an extraordinary opportunity to develop a world-class research centre with a particular emphasis on translating findings from basic science into novel diagnostic or therapeutic agents for patients who suffers from chronic disease burden of Qatar (cancer, diabetes and cardiovascular disease).I have returned to Oxford as Professor of Cancer Medicine, Radcliffe Dept of medicine and Chief medical Officer of Oxford Cancer Biomarker

This work was recognised by award of CBE (2002) by HM the Queen.

CLINICAL DUTIES and COLORECTAL CANCER RESEARCH

In Oxford I have joined the multidisciplinary gastro-intestinal cancer team, established a contract with the Danish Government to see and treat their refractory liver cancer patients, developed a gastrointestinal cancer study group within my Clinical Trials Unit and have accrued large patient numbers to local, national and international studies. Richard Gray and I ran QUASAR, a trial of adjuvant chemotherapy in colorectal cancer which successfully recruited 8500 patients in 8 years making it one of the largest and therefore potentially most influential cancer trials in the world. This has continued in Oxford with VICTOR, a placebo-controlled study of a selective COX-2 inhibitor, rofecoxib in an adjuvant setting for CRC which has recruited 2,500 patients. QUASAR 2 (3,750 patients) will compare standard chemotherapy versus Capecitabine and Bevacizumab, a regime which was developed in our own unit. This work has established the UK and my Unit as international leaders in the field of treatment and research into colorectal cancer. More recently, we have extended this work through collaboration with Prof Ian Tomlinson into the field of Genome Wide Association studies, with some notable success. I joined the Al Amal Hospital in Doha as Consultant Medical Oncologist and have been charged by Her Highness Sheikha Mozah with developing a cancer plan for the Nation.

Contribution to the field of colorectal cancer research and treatment was recognised in 1999 by the award of the 2nd International GI Cancer prize by the Institute for Drug Development and European Association for Research into Gastrointestinal Cancer and the ESMO award, 2006.

12

TRANSLATIONAL CANCER RESEARCH

I have been involved in cancer drug development for 30 years and established a phase I Trials Unit in the University of Birmingham, working later with Professor Lawrence Young to develop an MRC-funded virus-based gene therapy programme. I joined the Oxford Cancer Centre experimental trials group working with consultant colleagues, Prof Mark Middleton and Professor Adrian Harris with approximately 200-300 patients referred per annum for consideration of novel therapy with signal transduction inhibitors from the Pharma industry and our own account gene therapy programme (preclinical lead is Professor Len Seymour). I have conducted approximately 30 phase 1 trials.

Contribution to the field of gene therapy was recognised by award of the NHS’ first Nye Bevan award for Research Excellence.

ORGANISATIONAL LEADERSHIP

Academic (Universities of Birmingham and Oxford): As documented previously, I played a significant role in partnership with Alan Rickinson FRS, in establishing the CRC Institute for Cancer Studies in Birmingham and leading its development to one of the largest and best funded academic departments in the University of Birmingham. I was asked to do the same in Oxford, working closely with Sir John Bell, with a vision of constructing a comprehensive cancer centre which will be ranked amongst the top 10 in the world within 15 years of its inauguration. We have secured funding from the Department of Health for a new cancer hospital (£125 million) and have raised £60 million for the new laboratory. Importantly, in a time of increasing academic compartmentalisation, I established a series of collaborations across different divisions (Biomedical Engineering, Chemistry, Said Business School, Mathematics and Computer Science).

National Translational Cancer Research Network (NTRAC):I was commissioned by Secretary of State for Health to devise a costed blue print for provision of infrastructure to support clinical cancer research in the UK (NCRN and NTRAC). This was accepted and funded (£100 million) as part of the National Cancer Plan and I was subsequently appointed Director of NTRAC. This was a fascinating challenge, working with the best cancer research centres in the UK to forge them into a collaborative network, greater than the sum of its component points. International recognition of NTRAC’s ground breaking work has come in the form of invitations to; establish jointly funded translational science research fellowships between NTRAC and the NCI Washington and the French government’s Canceropoles; develop a European wide plan (ETRAC) to construct a Network of its top comprehensive cancer centres, along very similar lines to NTRAC; shape the Danish government’s plan to fund early clinical trial centres; provide intellectual underpinning for the US National Cancer Tissue Bank. NTRAC served as a ground breaking blue print for the other Department of Health innovations in forming research networks for cardiovascular disease, diabetes, mental health etc.

13

National Health Service, UK: Under the auspices of Brian Edwards, Chief Executive of West Midlands Regional Health Authority, I assembled a cancer services task force, developed a delivery strategy, and led the Regional team in its implementation over a 4 year period (1993-1997). This involved writing a Cancer Plan defining the relevant standards and the evidence base supporting these. The “hub and spoke” Network model which we elected to use has been developed further and incorporated into the National Cancer Plan, and we boiled the predicant philosophy down to four key elements:

Site specialisation by cancer surgeons and oncologists Multidisciplinary working Development of regional treatment guidelines (often precursor of national

guidelines) Use of IT as a social glue to bind the Network together.

This led to national investment in Cancer Services and fed forward into improving our National cancer survival figures and governmental investment of £670 million.

Department of Health: There are three National Programmes which I have led on behalf of the DH which have involved taking a strategic overview, finding effective solutions to complex problems and initiating cultural change in the NHS:National Audit of Cancer Waiting Times (1999): I delivered the first set of comprehensive data on cancer waiting times across the entire health service in England. This information was presented to ministers and was so profoundly disturbing, given the length of delays, that it was one of the dominant strands which resulted in creation of a National Cancer Plan - British Medical Journal 320, 838-839. Founding Commissioner For Health Improvement (1999-2001): I was invited to become a founding Commissioner stemming from an earlier piece of work in which I supported the main committee established to define CHI’s roles and responsibilities. I chaired the first review of the National Service Framework on Cancer Services, performed jointly with the Audit Commission (CHI-Audit Commission report on Cancer Services, 2000) its publication helped to highlight those areas of the cancer plan which were most vulnerable so that appropriate action might be taken and celebrate the obvious successes. Perhaps most importantly, we wrote this document so that it would be accessible to the lay reader and published a series of questions (in collaboration with the Guardian and Mirror) that patients could pose to their medical teams to ensure that they were getting optimal care.Cancer Services Collaborative (1999-2003): Seeing the need to reform the mode of delivery of cancer services, Helen Bevan (Director of Redesign, NHS Institute) and I secured funding to work with Don Berwick (Institute for Health Improvement, Boston) to create the Cancer Services Collaborative, the largest health care redesign programme ever undertaken. Results are detailed on web site (http://www.modern.nhs.uk), but in summary, significant gains were made in waiting times across the cancer patient’s journey, a much larger proportion of cancer patients were discussed by multidisciplinary teams and the quality of available patient information was greatly enhanced. This involved engagement with an initially sceptical clinical community and delivery of a complex National programme. The Cancer Services Collaborative involved expenditure of £30 million over 3 years, a staff of approximately 300 facilitators, managers and clinicians, which at its peak was reporting 1000 change episodes per month. We gained unique insights into large scale change management, the important elements of evincing clinical engagement, the problems associated with spread and sustainability of new practice and how we could use innovative communication practice to build a modernisation movement.National Framework for Service Change in NHS Scotland (2004-2005): I was invited by Scotland’s First Minister to chair the work of a National Framework Advisory Group to consider the future shape of the NHS in Scotland. We produced three volumes of work, “Building a Health Service Fit for the Future” (Vol I and II) and a web-based data link showing the Reports from the individual action teams

14

(www.show.scot.nhs.uk/national framework). The eponymous Kerr Report received strong support from citizens, health care professionals, unions (BMA and RCN), media and cross-party parliamentary endorsement. It has been adopted as the blueprint for Scotland’s NHS over the next 20 years.Sidra Medical and Research Centre (2009-2010): I was employed by Her Highness Sheikha Mozah, Consort of the Emir of Qatar to build the Research Division of the Sidra Medical and Research Centre, supported by the largest hospital endowment in the world ($9 billion) and an annual research budget rising to $200 million per annum. I practiced medicine at the local cancer hospital, Al Amal, and have been appointed to the Supreme Council of Health, effectively the Qatar’s Health Cabinet, and have been asked to support development of a National Health Plan. This position has allowed me to develop links with the wider world of Islam through the Organisation of the Islamic Conference (OIC), and I have been invited to build a Translational Research Network of the OIC’s top biomedical research Institutes.

Health Adviser to David Cameron and Conservative Party (2010-12 )I have supported the intellectual underpinning of the Health White Paper and provided a clinical Advisory role to David Cameron, Andrew Lansley and Conservative party.

INTERACTION WITH INDUSTRY

I have established board level links with a number of global pharmaceutical and healthcare companies which has led to significant grant funding eg Glaxo Smith Kline (£3 million), Merck (£14 million), Roche (£6.5 million) GE Healthcare (£2 million) and AstraZeneca (£1 million). I was part of the Drug Development Team which won Astra Zeneca’s Oncology and Infections Visions and Values prize in 2005.

Oxford has an impressive record of protecting and developing its IPR and establishing spin out companies. When working in the University of Birmingham, I established one of their first biotechnology spin outs, a gene therapy company, COBRA Therapeutics. In Oxford, I have worked with ISIS to construct a cancer drug development company, Celleron and Oxford Cancer Biomarkers a platform technology-based biotech company which identifies chemotherapy sensitivity biomarkers.

INTERNATIONAL COLLABORATIONS:

USA I sit on NIH’s Translational Research working group as the overseas member and have established a series of collaborations with the USA’s major cancer research centres (Mayo Clinic, MD Anderson, Memorial Sloan Kettering and Dana Farber, Harvard).

INDIA having attracted grant funding from the pharmaceutical company GSK, we have constructed a network of India’s top 10 cancer centres, in partnership with Oxford. This collaboration will provide training opportunities for Indian investigators in Oxford and will build an internationally competitive clinical research network (www.indox.org.uk).

15

EUROPE I had the opportunity to co-chair the Entente Cordiale Celebrations on behalf of HM the Queen and President Chirac, 2003-2005. As President of ESMO (2010-2012) I am in a strong position to improve standing of Medical Oncology in Europe and sit on the Dutch government’s central committee for translational research with a budget of 1 billion Euros.

AFRICA I have established a consortium comprising the International Atomic Energy Agency, International Agency for Cancer Research, and the Union Internationals Contre Le Cancer to develop cancer control programmes in Sub Saharan Africa and created AfrOx (www.afrox.org) the vehicle to implement change.

FAR EAST I have established OxOnics, a drug development company with my colleague Dr Wenn Sun. It has a mission to bring novel anti-cancer agents to the Asia-pacific rim with a focus on China.

RESEARCH GRANTS RECEIVED

1989

Health Board Research Support Group - £10,000.One year's salary for Research Assistant.

EEC (European against cancer initiative) - £230,000 over two years as part of an international collaborative group chaired by Prof S S Davis, Dept. Pharmacy, University of Nottingham

Cancer Research Campaign Project Grant - £160,000.3 years' salary - clinical research fellow & post doctoral scientist for research into use of Mitomycin C microcapsules by intrahepatic arterial administration in hepatic metastatic carcinoma. Grant Holders - D Kerr, C McArdle, A Whately.

1990

Scottish Hospital Endowment Research Trust- £44,0002 year's salary for research assistant - molecular biology of breast cancer

Cancer Research Campaign - £80,000 over 3 yearsJoint project with Dr I Pragnell, Beatson Institute for Cancer Research, funding a clinical research fellow to investigate preclinical toxicology of marrow stem cell inhibitor

1991

Scottish Hospital Endowment Research Trust - £75,0003 year salary for senior post-doctoral scientist for project on population pharmacokinetics of cytotoxic drugs in breast cancer therapy

Cancer Research Campaign - £200,000 per annumSupervision of programme grant expenditure of CRC Pharmacology Group - 5 year programme Grant.

1992

16

Scottish Hospital Endowments Research Trust - £50,0002 year's salary for senior post-doctoral scientist for project on formulation of cytotoxic drugs for cerebral implantation in the treatment of brain tumours. Grant Holders - D J Kerr, T A Whately, R Rampling, J Plumb

Queen Elizabeth Endowment Trust - £42,000Development of Inhibitors of P-Glycoprotein. Grant Holders - D J Kerr, D R Ferry

Queen Elizabeth Endowment Trust - £27,000Interaction of Platinum with the HIV Promoter Sequence. Grant Holders - D J Kerr, C J Poole, L Young

Cancer Research Campaign - £500,000Laboratory Refurbishment grant on joining University of BirminghamGrant Holder – D J Kerr

Cancer Research Campaign - £620,000Molecular Pharmacology GroupGrant Holder – D J Kerr

Cancer Research Campaign - £1 millionProgramme Grant Supporting Clinical Trials UnitGrant Holder – D J Kerr

1994

Regional Health Authority- £5 millionTo house the expanding Institute for Cancer Studies Grant holder - D J Kerr

September 1995-September 1999

Medical Research Council £1,501,304Gene Therapy of Common Cancers: Immunological & Pharmacological Approaches to Gynaecological Cancer. Grant holders - LS Young, PF Searle, D. Luesley, AB Rickinson, PH. Gallimore

Cancer Research Campaign £1.25 millionDepartments Expenses-Core Funding 1995-1999Grant holders - AB Rickinson and DJ Kerr

September 1994-September 1997

Glaxo Research and Development Limited (plc) - £75,000A Co-administration of rising oral GG918 Dose Levels with Doxorubicin Phase 1 StudyGrant holders - DJ Kerr

January 1995-January 1998

M.L. Laboratories plc - £75,794Adjuvant Intraperitoneal Chemotherapy with 5-fluorouracil in Duke’s Stage B and C Colic Adenocarcinoma (VICTOR)Grant holder - DJ Kerr

November 1995-November 1997

17

Special Trustees of the Former UBH Trust £49,233Investigation of Phospholipase Signal Transduction Pathways in Human Breast CancerGrant holders - DJ Kerr and MJO Wakelam

March 1997-March 1998

Takeda Chemical Industries Ltd. (Japan) £42,000A Phase II Open Label Study to Determine the Safety Tolerability and Efficacy of CV6504(HCI) in Patients with pancreatic cancerGrant holders - DJ Kerr

September 1996-September 1999

Glaxo-Wellcome R and D £120,000Immunological and Pharmacological Aspects of Gene TherapyGrant holders - DJ Kerr

1996-2001

Cancer Research Campaign £616,335Core Clinical FellowshipsGrant holders - DJ Kerr

1997-2001

Cancer Research Campaign £1,102,030Clinical Trials Unit – Core SupportGrant holders - DJ Kerr

1995-1998

Cancer Research Campaign £68,526West Midlands Trials of Adjuvant Treatment in Early Breast Cancer Grant holder - DJ Kerr

1998-2003

Cancer Research Campaign £534,695Pre-Clinical and Clinical Pharmacology and Macromolecular Drug TargetingGrant holder - DJ Kerr

1998-2002

Cancer Research Campaign £135,690ATTOM UKCCCR Randomised Trial to Establish Optimum Length of Adjuvant Tamoxifen Grant holder - DJ Kerr

1994-1997

Ministry of Agriculture, Fisheries and Food £200,742Evaluation of Non-Nutrient Dietary Constituents in Prevention of Breast Cancer Grant holders - DJ Kerr, A Gescher, K. Chipman

1997

The Higher Education Funding Council Capital £249,640

18

Research and Development for a Boron Cancer Therapy Clinical Facility Grant holders - DJ Kerr, N James, D. Beynon

1996-2001

NHS Research and Development Office £2.2 millionFoundation of a Regional Clinical Trials UnitGrant holders - DJ Kerr, R Hobbs, L Ward, J Dunn, J Kenkre

1994-1999

Medical Research Council £1.36 millionQUASAR Adjuvant Trial of Colorectal Cancer ChemotherapyGrant holders - DJ Kerr and R Gray

1998

Wellcome Trust £2.8 millionConstruction of a clinical research facilityGrant holders – M Sheppard, P Stewart, DJ Kerr, M Wakelam, LS Young, AB Rickinson, C Savage

1998-2003

Medical Research Council £403,608Co-operative Group – Translational Research: Gene and Immunotherapy of

Cancer.Grant holders: DJ Kerr, DH Adams, PAH Moss, V Mautner, PF Searle, L Seymour and LS Young

Medical Research Council £68,240Joint Research Equipment Initiative AwardGrant Holders: P Moss, A Rickinson, D Kerr, J Gordon, L Young C Bunce

1997-2002

Zeneca Pharmaceuticals £1,130,000Clinical Trials Grant for Adjuvant Colorectal Cancer Trial: PETACC

Medical Research Council £600,000FOCUS : trial of chemotherapy in advanced colorectal cancerGrant Holders: M Seymour, R James, D J Kerr, T Maugham and R Stephens

19

Recently awarded grants

MERCK – Cancer Research Campaign £12.6 million – 2002 – 2009Trial of adjuvant therapy with cyclooxygenase inhibitors in colorectal cancerGrant Holder: D J Kerr

Roche/Aventis – Cancer Research Campaign £4 million – 2004 - 2009Adjuvant trial of chemotherapy for colorectal cancerGrant Holder: D J Kerr

Genomic Healthcare £83,330 - 2006-2008Proteomic investigation of colorectal cancerGrant holder: D J Kerr

NHS R & D £20 million - 2001 – 2006To establish the National Translational Cancer Research Network (NTRAC) and the National Cancer Tissue Resource (NCTR).Grant Holder: D J Kerr

E-Science Pilot Project in Integrative Biology - £ 1,244 310Lead investigator: D GavaghanCo-investigator: D J Kerr CRUK Gene Therapy Programme Grant - £1.2 million - 2004 - 2009Lead investigator: L SeymourCo-investigator: D J Kerr

Genomic and proteomic approaches to identify novel Markers of Colorectal Cancer, MRC Co-operative Grant: £215,788 – 2004 -2007Lead investigators: D J Kerr and I Tomlinson

GE Healthcare: Molecular Basis of Colorectal Cancer - £2.4 million – 2005-2007Lead Investigator: D J Kerr

Cancer Research UK, Research Grant, ECMC Award - CRUK funding for the experimental cancer medicine centre - £3,070,410 - 2007 – 2012Lead investigator: A HarrisCo-investigator: D J Kerr

EUROCAN: £80,421- 2005 – 2007Lead investigator: P BoyleCo-investigator: D J Kerr

SCOT Study ad adjuvant colorectal cancer chemotherapy: MRC £1,798,433 – 2006- 2014Lead investigator: J CassidyCo-investigator: D J Kerr

Roche Ltd: £1.5 million – 2012 – currentLead Investigator: DJ Kerr

Oxford Cancer Biomarkers: £3.25 million – 2011- current

20

PUBLICATIONS

PUBLISHED ABSTRACTSOver 300 Abstracts presented at national and international conferences.

THESES

BSc: Degradation of the neuropeptide, metenkephalin by human plasma

MSc The clinical pharmacology of LM985 - an experimental cytotoxic drug

MD Aspects of cytotoxic drug penetration

PhD Regulation of proliferation of breast cancer cells by growth factors.

DSc The Molecular pharmacology of anticancer therapy

PEER REVIEWED PUBLICATIONS

In 4 sections: Colorectal Cancer; Drug Development; Gene Therapy; General Medicine

Section 1: Colorectal Cancer

Huijbers A, Tollenaar RAEM, Pelt GWV, Zeestraten ECM, Dutton S, McConkey CC, Domingo E, Smit VTHBM, Midgley R, Warren BF and Kerr DJThe proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the victor trialAnnals of Oncology 24(1):179-185 2013

Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson IUse of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3):441-448 Feb 2013

Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Almeida EG, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, The CORGI Consortium, Thomas HJ, Maher E, Evans G, Lucassen A, Cummings C, Stevens M, Walker L, Halliday D, Armstrong R, Paterson J, Hodgson S, Homfray T, Side L, Izatt L, Donaldson A, Tomkins S, Morrison P, Goodman S, Brewer C, Henderson A, Davidson R, Murday V, Cook J, Haites N, Bishop T, Sheridan E, Green A, Marks C, Carpenter S, Broughton M, Greenhalge L, Suri M, The WGS500 Consortium, Steering Committee:, Donnelly P, Bell J,

21

Bentley D, McVean G, Ratcliffe P, Taylor J, Wilkie A, Operations Committee:, Donnelly P, Broxholme J, Buck D, Cazier JB, Cornall R, Gregory L, Knight J, Lunter G, McVean G, Taylor J, Tomlinson I, Wilkie A, Sequencing & Experimental Follow-up:, Buck D, Gregory L, Humphray S, Kingsbury Z, Data Analysis:, McVean G, Donnelly P, Cazier JB, Broxholme J, Grocock R, Hatton E, Holmes CC, Hughes L, Humburg P, Kanapin A, Lunter G, Murray L, Rimmer A, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.Nat Genet 45(2):136-144 23 Dec 2012

Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, Kerr D, Oukrif D, Novelli M, Abulafi M, Hodgson SV, Fadhil W, Ilyas M, Tomlinson IP Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.Oncotarget 3(11):1348-1355 Nov 2012

Schmoll HJ, Van cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A Esmo consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology 23(10):2479-2516 2012

Kennedy RH, Francis A, Dutton S, Love S, Pearson S, Blazeby JM, Quirke P, Franks PJ, Kerr DJEnROL: A multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programmeBMC Cancer 12 2012

Kinnersley B, Migliorini G, Broderick P, Whiffin N, Dobbins SE, Casey G, Hopper J, Sieber O, Lipton L, Kerr DJ, Dunlop MG, Tomlinson IP, Houlston RS The TERT variant rs2736100 is associated with colorectal cancer riskBritish Journal of Cancer 107(6):1001-1008 2012

La Thangue, NB and Kerr DJ. Predictive biomarkers: a shift towards personalised cancer medicine Nature Reviews Clinical Oncology 8, 587-596,.2011

Kerr,DJ and Young AM. Targeted therapies:Bevacizumab – has it reached its final resting place? Nature Reviews Clinical Oncology 8, 195-196 , 2011

J Hecht, T Trarbach, J Hainsworth, P Major, E Jager, R Wolff, K Lloyd-Salvant, G Bodoky, K Pendergrass, W Berg, B Chen, T Jalava, G Meinhardt, D Laurent, D Lebwohl, and D Kerr. A Randomized, Placebo-Controlled, Phase III Study of First-line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584 (Vatalanib), an Oral VEGF Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma J Clin Oncol, 2011:1997-2003

22

Niedzwiecki D, Bertagnolli M, Warren S, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts SR, Porjosh GN , Kerr DJ, Fields, Goldberg< Mayer R, Colaccio TA Documenting the natural historyof patients with resection of stage2 adenocarcinoma of the colon after randomisation to Edrocolomab or observation. . J Clin Oncol , 11, 2011:3146-3152

Quirke P, Hutchins G, Southward K, Hardley K, Magill L, Beaumont C, Stahlschmidt J, Rickman S, Chambers P, Seymour M, Gray R and Kerr DJ. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol, 2011:1261-1270

Salazar R, Roepman P, Capella G, Moreno V, Simon I, López-Doriga1 A, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, M Glas A, Van ’t Veer L and Tollenaar R. A Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer J Clin Oncol, 1,2011:17-24

Gray R, Quirke P, Hardley K, Lopatin M, Magill L, aehner FL, Beaumont C, Clark-Langore KM, Yoshiwarza CN, Lee M, Watson D, Shak S and Kerr DJ. Validation Study of a Quantitative multi-gene RT-PCR assay as a predictor of recurrence in stage II colon cancer patient. J Clin Oncol, 12,2011:4611-4619

Houlston R, Cheadle J, Dobbins S, et al. Meta-analysis of three UK genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 42,973-77,2010.

Chen l, Zeng X, Wang J, Briggs SS, O’Neil E, Li J, Leek R, Kerr DJ, Harris AL, Cai L . Roles of Tetrahydrobiopterin in promoting tumour angiogenesis. Am J Pathol 2010 , 179: 2671-2680

Midgley RS, McConkey C, Kerr DJ et al. Final Results of the VICTOR Trial: A Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer. J Clin Oncol, 4575-4580, 2010.

Kerr DK and Midgley R. Defective Mismatch Repair in Colon Cancer: A prognostic or predictive biomarker? – Journal of Clinical Oncology, 3210-3212, 2010

The International Cancer Genome Consortium. Sequencing the cancer genome. Nature 2010 Apr 15;464(7291):993-8.

Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Letters 286 (2009) 114–120

Al-Salama H, Johnstone E and Kerr DJ. What Is the Role and Impact of Molecular Markers on Treatment Decisions for Colorectal Cancer in the Adjuvant Setting? Discovery Medicine. 2009. Discovery Medicine, volume 8, number 42, Pages 104-107.

Kerr DJ and Kakil IR. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced cancer. Nature Reviews Clinical Oncology. 2009 Sep;6(9):499-500

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr DJ.  Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009, 9: 489-499.

Luis S, Spain S, Tomlinson I, Kerr D; Houlston R, Cazier J. Common variation at the Adiponectin locus is not associated with colorectal cancer risk in the United Kingdom. Human Molecular Genetics, 18, 1889-1892, 2008.

23

Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20.

Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, De Gramont A, for the Adjuvant Colon Cancer Endpoints (ACCENT) Group16. Evidence for cure by adjuvant therapy in colon cancer: Observations Based on Individual Patient Data from 20,898 Patients of 18 Randomized Trials. : J Clin Oncol. 2009 Feb 20;27(6):872-7.

Midgley R, Kerr DJ. Capecitabine: have we got the right dose? Nature Clinical Practice. Vol 6: 1, 17-24. Oct 2008.

Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven N, Kerr DJ, Young LS, Adams DH. 3A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor Lysate in Patients with Hepatocellular Carcinoma. Hepatology. 2009 Jan;49(1):124-32. Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Minik, Evaristo E. Raltitrexed (Tomudex_) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). 2008. European Journal of Cancer, 44, 2004-2211.

Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier R, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van De Velde C, Zalcberg J. The diagnosis and management of rectal cancer. Expert discussion and recommendations derived from the 9th world congress on gastrointestinal cancer, Barcelona, 2007. Annals of Oncology. 19 (supplement 6): vii1-vi8, 2008

Kerr DJ. Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment. Nature Clinical Practice Oncology. Vol 5, 250-251.2008

Cogent Study Group Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genetics 40, 1426-35,2008

Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman A, Spain S , Lubbe S, Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A, Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington S, Tenesa A, Prendergast J, Barnetson R, Penegar S, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R, Maher E, Lucassen A, Kerr D, Evans E, The CORGI Consortium, Schafmayer C, Buch S, Izke H, Hampe J, Schreiber S, John U, Koessler T, Pharoah P, van Wezel T, Morreau H, Wijnen J, Hopper J, Southey M, Giles G, Severi G, Castellvı´-Bel S, Ruiz-Ponte C, Carracedo A, Castells A, The EPICOLON Consortium, Fo¨rsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, WC Ho J, Cheng K, Sham P, Luk J, Agu´ ndez J , Ladero J, de la Hoya M, Calde´s T, Niittyma¨ki I, Tuupanene S, Karhu A, Aaltonen L, CazierJB, Campbell H, Dunlop M, & Houlston R. A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics. 40, 623-630. 2008.

Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium, Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop

24

M, Thomas HH, Houlston R, Tomlinson I. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 40: 26-28, 2007.

Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E, Vijayakrishnan J, Kemp Z, Gorman M, Chandler I, Papaemmanuil E, Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L, Sieber O, Kerr D, Gray R, Peto J, Cazier JP, Tomlinson I, Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk. Nature Genetics 39, 1315 - 1317 (14 Oct 2007).

Sabharwal A and Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Review Anticancer Therapy. 7 (4), 477-487, 2007.

Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll H, Tabernero J, Tempero M, Van De Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th world congress on gastrointestinal cancer, Barcelona, 2006. Annals of Oncology. 18 (supplement 7): vii1-vii10, 2007.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Francois Seitz J, O'callaghan CJ, Francini G, Grothey A, O'connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, Gramont AD. End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. J Clin Oncol. 29: 4569-4574, 2007.

Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics 39, 984-988 (01 Aug 07)

Kerr DJ, Dunn JA, Langman MD, Smith JL, Midgley RJ, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC. Rofecoxib and Cardiovascular adverse events in adjuvant treatment of colorectal cancer. New England Journal of Medicine, 357:360-9. July 2007

Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group. Lancet, 370(9604):2020-9. 2007

Kerr David J. Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis? Nature Clinical Practice Oncology 3, 480 – 481. 2006.

Shimizu, Maruta F, Akita N, Miwa S, Seymour L, Kerr, D, Parker A, Miyagawa S. Identification of an oligopeptide binding to Hepatocellular carcinoma. Oncology 941. 2006

Russo, A, Bazan V, Iacopetta B, Kerr, D, Sonssi T, Gebbia N. The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumour Site, Type of Mutation, and Adjuvant Treatment. Journal of Clinical Oncology. 23: 2005, 7518-7528.

25

Sargent DJ, Wieand HS, Haller D G, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point of adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomised trials. Journal of Clinical Oncology. 2005, 23, No 34: pp. 8664-8670

Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.

Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., Büchler M. W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine. 350; 12. March 2004.

Chan, R and Kerr DJ. Can we individualise chemotherapy for colorectal cancer? Annals of Oncology. 15, 996-999, July 2004

Kerr D and Van Cutsem E. New approaches for the treatment of colorectal cancer in the adjuvant setting. Eur J Cancer. Vol 2 No 7, 34-39. 2004

Grabsch H, Kerr D and Quirke P. Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours?. Histopathology. 45, 312-334. 2004

Kerr D. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical Practice, Oncology. Vol 1, 39-43, 2004

Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003) 3 615-622.

Grumett, SA and Kerr DJ. Irinotecan and Capecitabine in a patient with advanced colorectal cancer. Case Studies in Colorectal Cancer. (August 2003), Vol2, No.5.

Nicum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol. 2003;42(4):263-75.

Kerr, D.J., McArdle, C.S; Ledermann, J; Taylor, I; Sherlock, S.J; Schlag, P.M; Buckels, J; Mayer, D; Cain, D; Stephens, R.J. Intrahepatic arterial versus intravenous 5 fluorouracil and leucovorin for colorectal cancer liver metastases: results of a multicentre randomised trial, Lancet, 2003, 361,368-373

Midgley, RS; Kerr, D.J. Immunotherapy for colorectal cancer. Expert Rev. Anticancer Ther. 3(1), 63-78, 2003.

Maughan TS, James RD, Kerr D, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ on behalf of the MRC Colorectal Cancer Group Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal: a multicentre randomized trial. Lancet, 2003;361:457-64

Hosie KB, Kerr DJ, Gilbert JA, Downes M, Lakin G, Pemberton G, Timms K, Young A and Stanley A. A Pilot study of adjuvant intraperitoneal 5-fluororuarcil using 4% icodextrin as a novel carrier solution. European Journal of Surgical Oncology. (2003) 29: 254-260

Pendlebury S, Duchesne F, Reed K, Smith JL and Kerr DJ. A trial of adjuvant therapy in colorectal cancer: The VICTOR Trial. Clinical Colorectal Cancer. (2003) Vol 3:1. 58-60

26

Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P and Schmoll HP. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin 2001) European Journal of Cancer. 2002, 38, 1429-1436.

Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359, 1555-1563

Midgley RS, Kerr DJ (2002) Ras as a target in Cancer Therapy. Critical Reviews in Haematology and Oncology 44(2):109-120

Tebutt NC, Cattell E, Midgley RS, Cunningham D, Kerr DJ. (2002) Systemic therapy of colorectal cancer. Eur.J.Oncol. 38(7): 1000-1015

Nicum S, Midgley RS, Kerr DJ (2002) Chemotherapy and Radiotherapy for Colorectal Cancer. In:Recent Advances in Coloproctology-Volume 2. In press

Kerr, D.J.,and Midgley, R.S. (2002). Immunotherapy for colorectal cancer: potential application in an adjuvant setting. Semin Oncol 27, 132-7.

Hussain, S.A., Ferry, D.R., El-Gazzas, G., Mirza, D.F., James, N.D., McMaster, P., and Kerr, D.J. (2001). Hepatocellular carcinoma. Ann Oncol 12, 161-72.

Kerr DJ. A United Kingdom Coordinating Committee on Cancer Research Study of Adjuvant Chemotherapy for Colorectal Cancer: Preliminary Results. Seminars in Oncology, 28(1): 31-34 (2001)

Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM. Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% Icodextrin. Drug Delivery, 8: 9-12 (2001).

Neoptolemos JP, Dunn JA, Moffitt DD, Almond J, Link K, Beger H, Bassi C, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Spooner D*, Kerr DJ*, Friess H, Buchler M. European Study Group for Pancreatic Cancer-1 interim results: a European randomized study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. British Journal of Surgery 2001;88(3):475-

Neoptolemos, J.P; Dunn,J.A; Stocken,D.D; Almond,J; Link,K; Beger,H; Bassi,C; Falconi,M; Pederzoli,P; Dervenis,C; Fernandez-Cruz,L; Lacaine,F; Pap,A; Spooner,D; Kerr,D.J; Friess,H; Buchler,M.W. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. European-Study-Group-for-Pancreatic-Cancer. Lancet. 2001 Nov 10; 358(9293): 1576-85

Snow,P.B; Kerr,D.J; Brandt,J.M; Rodvold, D.M Neural network and regression predictions of 5-year survival after colon carcinoma treatment. Cancer. 2001 Apr 15; 91: 1673-8

Grumett,S.A; Archer,V.R; Midgley,R; Mulholland,P; Nicum,S; Blewitt,L; Kerr,D.J. The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy. Ann-Oncol. 2001 Apr; 12(4): 575

Kerr, D.J. Two cultures or two faces? Ann-Oncol. 2001 Jan; 12(1): 7-8

Young,A.M; Kerr,D.J. Home delivery: chemotherapy and pizza? British Medical Journal. 2001 Apr 7; 322(7290): 809-10

27

Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001; 358:1291-1304

Gray RG, Kerr DJ, McConkey CC, et al. On behalf of QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. The Lancet, 355, 1588-96 (2000)

Midgley RS, Kerr DJ. Towards post-genomic investigation of colorectal cancer. Lancet, Feb 26; 355 (9205): 669-70 (2000)

Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M. New directions in the treatment of colorectal cancer: a look to the future. European Journal of Cancer, 36, 559-566 (2000)

Nicum S, Midgley RS, Kerr DJ. Chemotherapy of colorectal cancer. Journal of the Royal Society of Medicine, 93, 416-419 (2000)

Midgley, R, Kerr D. Immunotherapy for colorectal cancer: a challenge to clinical trial design. The Lancet, 159-168 (2000)

Chung-Faye, G.A.,and Kerr, D.J. (2000). ABC of colorectal cancer: Innovative treatment for colon cancer. British Medical Journal 321, 1397-9.

Midgley, R.S. and Kerr, D.J. (2000). ABC of colorectal cancer: adjuvant therapy. British Medical Journal 321, 1208-11.

Kerr DJ, Gray R, McConkey C, Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. Annals of Oncology 2000;11(8):947-955

Kerr, D.J., Midgley, R.J., and McArdle, C.S. (2000). Hepatic arterial chemotherapy; Still on trial. Journal of Clinical Oncology 18, 1806-1807.

Kerr, D.J. (1999). Cost of treating colorectal cancers. European Journal of Cancer 35, 187.

Midgley R, Kerr D, Seminar on Colorectal Cancer. Lancet Vol. 353: 391-99 (1999)

Koehne CH, Midgley R, Seymour M, Kerr DJ. Advanced colorectal cancer: which regimes should we recommend? Annals of Oncology Aug; 10(8):877-82 (1999)

Ingleby, S., Barnwell, J., Baker, J.,Harvey, P., kerr, D.J., Law, V., and Young, A. (1999). A pilot study of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer. European Journal of Cancer 35, 214.

Jessop, J.M., Snow, P., Brandt, J., Bellucco, C., Menck, H.R., and Kerr, D.J. (1999). Artificial neural network prediction of 5-year survival from colon cancer. European Journal of Cancer 35, 211.

28

Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma sequence in the esophagus. American Journal of Pathology Vol. 154 (4) (1999)

Langman MJS, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JWL, Kerr DJ. Prospective, double-blind, placebo-controlled randomised trial of cimetidine in gastric cancer. British Journal of Cancer, 81(8), 1356-1362 (1999)Howell JD, Warren HW, Anderson JH, Kerr DJ, and McArdle CS. Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer. European Journal of Surgery 1999; Vol 165.652-8.

Young AM, Kerr DJ Novel Treatments for Colorectal Cancer, Oncology Today – 1999 18-26

Young AM, Daryanani S, and Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clinical Pharmacokinetics 1999; 36.391-8.

Ingleby, S., Baker, J., Young, A., and Kerr, D.J. (1999). Health economics analysis of home based vs. hospital based chemotherapy: Discussion of results. British Journal of Cancer 80, 332.

Kerr, D. (1999). Safety of Raltitrexed. Lancet 354, 1825.

Kerr DJ, Ferry DR, Novel therapeutic strategies for colorectal cancer. Hospital Medicine, Vol. 59, No. 8: 617-621, (1998)

Cocconi G, Cunningham, D, Van Cutsem E, Francois E, Gustavsson B, van Hasal G, Kerr D, Possinger K, Hietschold SM. Open, randomized , multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Onc. 16, 9 : 2943-2952, (1998)

Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is signjificantly associated with gender, increasing age and cycle number. Tomudex International Study Group. European Journal of Cancer, 34 (12): 1871-5 (1998)

Wils J, Sahmoud T, Sobrero A, Bleiberg H, Ahmedzai S, Blazeby J, Blijham G, Conroy T, Cunningham D, Curran D, Diaz-Rubio E, Ducreux M, Evans J, Glimelius B, Hutchinson G, Kerr D et al. Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organised by the EORTC GITCCG. European Organisation for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Tumori 1998; 84.335-47.

Baker, J., Bleiberg, H., Hutchison, G., Jackman, A., Kerr, D., Labianca, R., Macdonald, J., Meyer, H.J., Minsky, B., Nordlinger, B., Rougier, P., Smits, S., Sobrero, A., Taylor, I., and Verweijm J. An international multidisciplinary approach to the management of advanced colorectal cancer (First of two parts) (Reprinted from Eur J Surg Oncol, Vol 23, Suppl A, August 1997) Annales Chirurgiae Et Gynaecologiae 87, 255-264. (1998).

Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Miller A. Combined Analysis of studies of the effects of the matrix metalloprote4inase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer Research. Vol. 4: 1101-1109, May 1998

29

Seymour LW, Olliff SP, Poole CJ, de Takats PG, Orme R, Ferry DR, Maeda H, Konno T, Kerr DJ. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) – neocarzinostatin] in the treatment of primary hepatocellular carcinoma. International Journal of Oncology 12: 1217-12223, (1998).

Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis E and Seymour LA Phase II study of raltitrexed ‘Tomudex’ in patients with hepatocellular carcinoma. Annals of Oncology 8: 500-502 (1997)

Kerr DJ, O’Connor K.M. The costs of managing advanced colorectal cancer: a broad perspective. Anti-Cancer Drugs Vol. 8, Suppl 2 1997 S23 (1997)

Neoptolemos JP, Kerr DJ, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Laçaine F, Freiss H, Büchler M. ESPAC-1 Trial Progress Report. The European randomised adjuvant study comparing radiochemotherapy, six months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion: 56: 570-577 (1997)

Midgley RS, Kerr DJ. Adjuvant Therapy of Colorectal Cancer. Cancer Treatment Reviews 23:135-152. (1997)

Blesing, CH, Julyan, PJ, Barnwell, JM, Parker, DJ, Mountford, PJ, Kerr, DJ, and Harding LK Quantitative whole body counter distribution studies of 18f-5 fluorouracil following hepatic arterial and IV infusion. Br. J. Radiology, 32, 14-19 (1996)

Blesing, CH; Kerr, DJ. Intra-hepatic arterial drug delivery. J Drug Targeting 3: 341-347 (1996)

Green, NK, Searle, PF, Young, LS, Kerr, DJ and Neoptolamos JP Gene Therapy for gastrointestinal cancer, GI Cancer, 2, 43-53 (1996)

De Takats, PG and Kerr DJ Is intra-arterial chemotherapy worthwile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Eur.J.Cancer 32 13, 2195-2205 (1996)

Kerr, DJ, Young, AM, Neoptolamos, JP, Sherman, J, Van-Geere, P, Stanley, A, Ferry, D, Dobbie, JW, Vincke, B, Gilbert, J, Dombros, N, and Fountzilos, G.. Prolonged Introperitoneal infusion of 5-FU using a novel carrier solution. Brit. J. Cancer, 74, 2032-2035 (1996)

McArdle, CS; Anderson, JH; Warren, H; Doughty, J; Kerr, DJ. Intra-arterial 5-FU modulated by folinic acid for colorectal liver mets.Regional Cancer Treat. 9: 27-29 (1996)

Kerr, DJ. Tomudex ZD 1694, a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer. Quality of Life Research 4 6: 576 (1995)

Kerr, DJ; de Takats, PG Chemotherapy for gastrointestinal cancer: teaching old drugs new tricks. GI Cancer 1: 3-7 (1995)

Kerr, DJ; Ledermann, JA; McArdle, CS; Buckels, J; Neoptolemos, J; Seymour, M; Doughty, J; Budden, J; Taylor, I. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 1312: 2968-2972 (1995)

Kerr, DJ; Rustin, GJ; Kaye, SB; Selby, P; Bleehen, NM; Harper, P; Brampton, MH.Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer 72: 1267-1269 (1995)

30

Cunningham, D; Zalcberg, JR; Rath, U; Olver, I; Van Cutsem, E; Svensson, C; Seitz, JF; Harper, P; Kerr, D; Perez-Mango, G; Azab, M; Seymour, L; Lowery, K & the ‘Tomudex’ Colorectal Cancer Study Group Tomudex ZD1694: Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A 12: 1945-1954 (1995)

Jodrell, DI; Oster, W; Kerr, DJ; Canney, PA; Yosef, H; Steward, WP; Kaye, SB; Cassidy, J. A phase I/II study of N-phosphonacetyl-L-Aspartic Acid PALA added to 5-Fluorouracil and folinic acid in advanced colorectal cancer. Eur J Cancer 30a 7: 950-954 (1994)

de Takats, PG; Kerr, DJ; Poole, CJ; Warren, HW; McArdle, CS. Hepatic arterial chemotherapy for metastatic colorectal carcinoma.Br J Cancer 69: 372-378 (1994)

McArdle, CS; Kerr, DJ; O’Gorman, P; Wotherspoon, HA; Warren, H; Watson, D; Vinke, BJ; Dobbie, JW; El Eini, DID. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 70: 762-766(1994)

Warren, HW; Anderson, JH; O’Gorman, P; Kane, E; Kerr, DJ; Cooke, TG; McArdle, CS. A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer 70: 677-680 (1994)Warren, HW; Anderson, JH; O'Gorman, P; Kerr, DJ; Cooke, TG; McArdle, CS. Ambulatory infusion pumps for intrahepatic arterial chemotherapy. Regional Cancer Treat 2: 77-78 (1993)

McArdle, CS. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Anderson, JH; Goldberg, JA; Bessent, RG; Kerr, DJ; McKillop, JH, Stewart, I; Cooke, TG; Radiotherapy and Oncology 25: 137-139. 1992

Anderson, JH; Kerr, DJ; Cooke, TG; McArdle, CS. A phase I study of regional 5-Fluoruracil and systemic folinic acid for patients with colorectal liver metastases. Br J Cancer 65: 913-915. 1992

Anderson, JH; Kerr, DJ; Setanoians, A; Cooke, TG; McArdle, CS. A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.Br J Cancer 65: 133-135. 1992

Kaye, SB; Brampton, M; Harper, P; Smyth, J; Kerr, DJ; Gore, M; Green, JA; Gilby, E; Crawford, SM; Rustin, GJ. Phase II trials of fosquidone, GR63178A in colorectal, renal and non-small cell lung cancer. Br J Cancer 65: 624-625. 1992

Kerr, DJ 5-fluorouracil and folinic acid - interesting biochemistry or effective treatment?Brit J Cancer 60 6: 807-809. 1989

31

Section 2: Drug Development and Pharmacology

Khan O, La Thangue, Kerr et al. "HR23B is a biomarker for tumour sensitivity to HDAC inhibitor-based therapy." Proc Nat Acad Science –107(14):6532-7. 2010.

Rahman N M, Davies HE, Salzberg M, Truog P, Midgely R, Kerr D, Clelland C, Hedley EL, Lee YCG, Davies RJO. Use of lipoteichoic acid-T for pleurodesis in malignant pleural eff usion: a phase I toxicity and dose-escalation study. Lancet Oncology. 2008. 1016/S1470-2045(08)70205-5.

Middleton M, Knox C, Cattell E, Opperman U, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Harlley J and Kerr DJ. Quinone Oxido-reductase-2-mediated Prodrug Cancer Therapy. Science Translational Medicine, 2, 420-428, 2010

Edwards AM, Bountra C, Kerr DJ, Willson TM. Open access chemical and clinical probes to support drug discovery. Nat Chem Biol. 2009 Jul;5(7):436-40

Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Calver H, Lind M, Robbins A, Burtles S, Duncan R and Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology. 2009 Jun;34(6):1629-36.

Midgley R, Kerr D, Flaherty K, Stevenson JP, Pratap S, Koch K, Smith D, Versola M, Fleming R, Ward C, O'Dwyer P and Middleton M. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology 2007 18(12):2025-2029.

Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Single-dose clinical pharmacokinetic studies of gefitinib. Clinical Pharmacokinetics. 2005;44(11):1165-77

Kerr DJ, La Thangue N. Signal transduction blockade and cancer : combination therapy or multi-targeted inhibitors? Annals of Oncology, 15: 1727-1729, 2004

Danson S, Ferry D, Alkhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G and Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. 2085-2091,2004

Knox RJ, Burke PJ, Chen S, Kerr DJ. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des. 2003;9(26):2091-104.

Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 2002;9(3):287-300

Seymour, L.W., Ferry, D.R., Anderson, D., Doran,J, Young, A.M., Kerr, D.J., Hesselwood,S., Julyan, P.J., Poyner, R. and Burtles, S., Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin J-Clin-Oncol. 2002 Mar 15; 20(6): 1668-76

Taylor,-P-M; Woodfield,-R-J; Hodgkin,-M-N; Pettitt,-T-R; Martin,-A; Kerr,-D-J; Wakelam,M.J. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene. 2002 Aug 22; 21(37): 5765-72

32

Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr DJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology 2001;12(2):245-248

Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJO, Doran J, Pemberton G, Young AM, Buckels J & Kerr DJ. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology, 11, 1165-1170 (2000).

Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S and Kerr DJ. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 1999; 57.281-90.

Anderson, D., Ferry, D.R., Knox,R.J., Andrews, S.J., Downes, A.J., Kerr, D.J., and Seymour, L.W. (1999). High-performance chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma. Journal of Chromatography B 731, 293-298.

Harper, A., Kerr, D.J., Gescher, A., and Chipman, J.K. (1999). Antioxidant effects of isofavonoids and lignans, and protection against DNA oxidation. Free Radical Research 31, 149-160.

Harper A, Kerr DJ, Gescher A and Chipman JK. Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. Free Radical Res., 31, 149-160 (1999)

Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J. The effect of Cimetidine on the pharmacokinetics of Epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clinical Oncology 10:35-38 (1998)

Helsby NA, Chipman JK, Gescher A and Kerr DJ. Inhibition of mouse and human CYP 1A-and 2E1-dependent substrate metabolism by the isoflavonoids Genistein and Equol. Food and Chemical Toxicology, 36, 375-382 (1998)

Schultze-Mosgau M, Dale IL, Gant TW, Chipman JK, Kerr DJ and Gescher A. Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. Europ. J. Cancer,Vol 34 : 9, 1425-1431 (1998)

Helsby NA, Chipman JK, Gescher A and Kerr D. Inhibition of carcinogen-activating cytochrome P450s by potential chemopreventative agents genistein and equol. Food Chem. Toxicol. 36, 568-577

Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ. Anti-proliferative activity and mechanism of action of titanocene dichloride. British Journal of Cancer 77(12: 2088-2097 (1998)

Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Elipoulos A, Hale K, Baumgart J, Sass G, Kerr David J. Phase I Trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J. Clin. Oncol 16: 8 2761-2769 (1998)

33

Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S Kerr DJ. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 57: 281-290 (1998)

Anderson, D; Kerr, DJ; Blesing, C; Seymour, LW Simultaneous gas chromatographic-mass spectrophotometric determination of a-fluoro-b-alanine and 5-fluorouracil in plasma. J Chromatogr. 688, 87-93 (1997)

Helsby NA, Williams, J, Kerr, D, Gescher, A, Chipman, JK. The isoflavones equol and genistein do not induce xenobiotic-metabolising enzymes in mouse and in human cells.Xenobiotica, Vol. 27, 6: 587-596 (1997)

Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P, Wakelam MJO. Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. Biochimica et Biophysica ACT 1362 29-38 (1997)

Helsby NA, Williams J, Kerr D, Gescher A and Chipman JK. The isoflavones equol and genistein do not induce xenobiotic-metabolising enzymes in mouse and in human cells. Xenobiotica 27, 587-596 (1997)

Seymour, LW; Shoaibi, MA; Martin, A; Ahmal, A; Elvin, P; Kerr, DJ and Wakelam MJO Vascular endothelial growth factors stimulates protein kinase C dependent phospholipase D activity in endothelial cells. Lab.Invest. 75 3, 427-437 (1996)

Ferry, DR; Smith, A; Malkhandi, J; Fyfe, DW; de Takats, PG; Anderson, D; Baker, J; Kerr, DJ Phase I trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Res 2: 659-668 (1996)

Eliopoulos AG, Dawson CW, Mosialos G, Floettmann J Eike, Rowe M, Armitage, RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJO, Reed JC, Kieff E and Young LS. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 13, 2243-2254 (1996)

Eliopoulos, AG; Kerr, DJ; Herod, J; Hodgkins, L; Krajewski, S; Reed, JC; Young, LS The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228 (1995)

Eliopoulos, AG; Kerr, DJ; Maurer, HR; Hilgard, P; Spandidos, DA. Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem Pharmacol 50 1: 33-38 (1995)

Ferry, DR; Malkhandi, PJ; Russell, MA; Kerr, DJ. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 12: 1851-1861(1995)

Cross, MJ; Stewart, A; Hodgkin, MN; Kerr, DJ; Wakelam, MJO. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells. J of Biological Chem, 270 43: 25352-25355 (1995)

Liu, B; Anderson, D; Ferry, DR; Seymour, LW; de Takats, PG; Kerr, DJ.Determination of quercetin in human plasma using reverse-phase high-performance liquid chromatography. J Chromatography B, 666: 149-155 (1995)

Liu, B; Earl, HM; Poole, CJ; Dunn, J; Kerr, DJ Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 36: 506-512 (1995)

34

Liu, B; Earl, HM; Baban, DF; Shoaibi, M; Fabra, A; Kerr, DJ; Seymour, LW Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Comm 217 3: 721-727. (1995)

Ferry, DR; Kerr, DJ Multidrug resistance in cancer. Br Med J 308: 148-149 (1994)

Malkhandi, J; Ferry, DR; Boer, R; Gekeler, V; Ise, W; Kerr, DJ. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol Mol. Pharmacol. Section 288: 105-114 (1994)

Wishart GC; Bissett, D; Paul, J; Jodrell, D; Harnett, A; Habeshaw, T; Kerr, DJ; Macham, MA; Soukop, M; Leonard, RCF, Knepil, J; Kaye, SB Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo controlled randomized trial. J Clin Oncol 12 9: 1771-1777 (1994)

Cross, MJ; Stewart, A; Plumb, J; Mcauley, G; Hill, RA; Isaacs, N; Workman, P; Kerr, D; Wakelam, MJO Inhibition of phospholipases and cell proliferation by demethoxyviridin. J Cellular Biochem. S18D: 56 (1994)

Kerr, DJ. Phase I clinical trials: adapting methodology to face new challenges. Annals Oncol 5 4: S67-S70 (1994)

Morrison, JG; Bissett, D; Stephens, IFD; McKay, K; Brown, R; Graham, MA; Fichtinger-Schepman,AM; Kerr, DJ. The isolation and identification of cis-diamminedichloroplatinum II-DNA adducts by anion exchange HPLC and inductively coupled plasma mass spectrometry. Int J Oncology 2: 33-37 (1993)

Plumb, JA; Luo, W; Kerr, DJ. Effect of polyunsaturated fatty-acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67 4: 728-733 (1993)

Kerr,DJ; Los,G. Ph armacokinetic principles of locoregional chemotherapy. Cancer Surveys 17: 105-122 (1993)

Bissett, D; Setonoians, A; Cassidy, J; Graham, M; Chadwick, GA; Wilson, P; Auzanet, V; LeBail, N; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of taxotere RP 56976 administered as a 24-hour infusion. Cancer Res 53: 523-527 (1993)

Cassidy, J; Graham, MA; Huinink, WT; McDaniel, C; Setanoians, A; Rankin, EM; Kerr, DJ; Kaye, SB for the EORTC ECTG. Phase I clinical study of LL-D49194a1 with retrospective pharmacokinetic investigations in mice and humans. Cancer Chemother Pharmacol 31 5: 395-400 (1993)

Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Differential Interaction of Cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. Anti-Cancer Drugs 4: 77-83 (1993)

Dunlop, DJ; Wright, EG; Lawrence, S; Graham, GJ; Holyoake, T; Kerr, DJ; Wolfe, SD; Pragnell, IB. Demonstration of Stem cell inhibition and myeloprotective effects of SCI/rhMIPIa in vivo. Blood 79 9: 2221-2225. 1992

Bisset, D; Graham, MA; Setanoians, A; Chadwick, GA; Wilson, P; Koier, R; Henrar, R; Schwartsmann, G; Cassidy, J; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52: 2894-2898. 1992

Wade, JR; Kelman, AW; Kerr, DJ; Robert, J; Whiting, B Variability in the pharmacokinetics of epirubicin : a population analysis. Cancer Chemother Pharmacol 29: 391-395. 1992

35

Zoumpourlis, V; Kerr, DJ; Spandidos, DA Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. Biochem Pharmacol 43 3: 650-654. 1992

Bissett, D; Kaye, SB; Kerr, DJ. Can primary osteosarcoma act as a third space after high dose methotrexate?. Eur J Cancer 27: 1060. 1992

Goldberg, JA; Willmott, N; Kerr, DJ; Sutherland, C; McArdle, CS. An in vivo assessment of adriamycin-loaded albumin microspheres. Br J Cancer 65: 393-395. 1992

Scott, RN; Blackie, R; Kerr, DJ; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 28a 11: 1811-1813. 1992

Scott, RN; Kerr, DJ; Blackie, R; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer. 66: 159-166. 1992

Cassidy, J; Bissett, D; Kerr, DJ. Methodological aspects of phase I studies of novel anti-cancer agents Review. Int J Oncol 1: 195-199. 1992

Graham, MA; Bissett, D; Setanoians, A; Kerr, DJ. Pre-clinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme. J National Cancer Inst 84: 494-500. 1992

Bissett, D; Kerr, DJ; Cassidy, J; Meredith, P; Traugott, U; Kaye, SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171. 1991

Eliopoulos, A; Kerr, DJ; Spandidos, DA. The effect of doxorubicin, daunorubicin and 4’-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukaemia cells. Anticancer Res 11: 2153-2158. 1991

Graham, MA; Riley, RJ; Kerr, DJ. Drug metabolism in carcinogenesis and cancer chemotherapy. Pharmac Ther 51: 275-289. 1991

Kaye, SB; Kerr, DJ. Multidrug resistance : Clinical relevance in haematological malignancies. Blood Reviews 6: 39-42. 1991

Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. Cancer Letters 56: 181-185. 1991

Goldberg, JA; Kerr, DJ; Blackie, R; Whately, TL; Pettit, L; Kato, T; McArdle, CS.Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Cancer 67: 952-955. 1991

Goldberg, JA; Murray, T; Kerr, DJ; Willmott, N; Bessent, RG, McKillop, JH; McArdle, CS.The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer 63: 308-310. 1991

Cytotoxic-loaded microspheres in patients with colorectal liver metastases.Br J Cancer 64: 114-119. 1991

Kerr, DJ; Kaye, SB.Chemoembolism in cancer chemotherapy. Critical Reviews in Therapeutic Drug Carrier Systems 8 1: 19-37. 1991

Eliopoulos, A; Kerr, DJ; Spandidos, DA The effect of cisplatin and carboplatin on c-myc promoter in erythroleukaemic cells. Anticancer Drugs 2: 597-601. 1991

36

Kerr, DJ; Plumb, JA; Freshney, RI; Khan, MZ; Spandidos, DA The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs. Anticancer Res 11: 1349-1352. 1991

Wishart, GC; Plumb, JA; Spandidos, DA; Kerr, DJ H-ras transfection in mink lung epithelial cells may induce “atypical” multidrug resistance. Eur J Cancer 27 5: 673. 1991

Anderson, JH; Goldberg, JA; Eley, JG; Whateley, TL; Kerr, DJ; Cooke, TG; McArdle,CS A Phase I study of regionally administered mitomycin microcapsules for patients with colorectal liver metastases.Eur J Cancer 27 9: 1189-1190. 1991

Thomson, AM; Kerr, DJ; Steel, CM Transforming growth factor b1 is implicated in the failure of Tamoxifen therapy in human breast cancer. Br J Cancer, 63: 609-614. 1991

Jones, RD; Kerr, DJ; Harnett, AN; Rankin, EM; Ray, S; Kaye, SB. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62: 133-135. 1990

Kerr, DJ; Kaye, SB. Multidrug resistance in haematological malignancies. Haematology Reviews 4: 61-64. 1990

Kerr, DJ; Khan, MZ; Plumb, JA; Freshney, RI; Spandidos, DA. The effect of oncogene transfection on epithelial cell response to cytotoxic drugs. Biochem Pharmacol 9: 375-379. 1990

Goldberg, JA; Kerr, DJ; Stewart, I; McArdle, CS. A comparison of regional and systemic chemotherapy for hepatic metastases.Eur J Surg Oncol 16: 464-467. 1990

Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, J; McArdle, CS. Regional chemotherapy for colorectal liver metastases : a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.Br J Surgery 77: 1238-1240. 1990

Carmichael, J; Cantwell, KA; Mannix, KA; Veale, D; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL.A phase I and pharmacokinetic study of didox admistered by 36 hour infusion. Br J Cancer 61: 447-450. 1990

Kerr, DJ; Slack, JA; Secrett, P; Stevens, MFG; Blackledge, GRP; Bradley, C; Kaye, SB. Relationships between the pharmacokinetics and toxicity of mitozolamide. Cancer Chemother Pharmacol 25: 352-354. 1990

Kerr, DJ; Lewis, C; O'Neil, B; Lawson, N; Blackie, R; Newell, DR; Roball, F; Cox, J; Rankin, EM; Kay, SB The myelotoxicity of carboplatin is influenced by the time of its administration. Haematol Oncol 8: 54-65. 1990

Goldberg, JA; Kerr, DJ; Watson, DG; Willmott, N; Bates, CD; McKillop, JH; McArdle, CS The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.Br J Cancer 62: 78-85. 1990

Lewis, C; Lawson, N; Rankin, EM; Morrison, G; MacLean, AB; Cordiner, J; Cassidy, J; Kerr, DJ; Kaye, SB Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.Cancer Chemother Pharmacol 26: 283-287. 1990

Cummings, J; Double, JA; Bibby, M; Farmer, P; Evans, S; Kerr, DJ; Kaye, SB; Smyth, JF. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res 49: 3587-3593. 1989

Kerr, DJ; Kaye, SB. Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25 9: 1271-1272. 1989

37

Kerr, DJ; Pragnell, IB; Sproul, A; Cowan, S; Murray, T; George, D; Leake, R The cytostatic effects of a-interferon may be mediated by transforming growth factor-b. J Molec Endocrin 2: 131-136. 1989

Kerr, DJ; Maughan, T; Newlands, E; Rustin, G; Bleehen, NM; Lewis, C; Kaye, SB. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60: 104-106. 1989

Kerr, DJ; Hynds, S; Shepherd, J; Packard, CJ; Kaye, SB. Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. Biochem Pharmacol 37 20: 3981-3986. 1988

Kerr, DJ; Rogerson, A; Morrison, GJ; Florence, AT; Kaye, SB. Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br J Cancer 58: 432-436. 1988

Kerr, DJ; Wheldon, TE; Hynds, S; Kaye, SB. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica, 18 6: 641-648. 1988

Goldberg, JA; Fenner, J; Bradnam, MS; Bessent, RG; McKillop, JH; Kerr, DJ; McArdle, CS.Improved tumour targeting of biodegradable microspheres with angiotensin II. Br J Surgery 75 12:1262. 1988

Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, JH; McArdle, CS.Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil 5FU in advanced colorectal liver metastases.Br J Cancer 57: 186-189. 1988

Kerr, DJ; Willmott, N; Levi, H; McArdle, CS.The pharmacokinetics and disposition of adriamycin loaded albumin microspheres following intra renal arterial administration.Cancer 62: 878-882. 1988

McArdle, CS; Lewis, H; Hansell, D; Kerr, DJ; McKillop, J; Willmott, N.Cytotoxic loaded albumin microspheres : a novel approach to regional chemotherapy.Br. J Surg 75: 132-134. 1988

Gouyette, A; Kerr, DJ; Kaye, SB; Setanoians, A; Cassidy, J; Bradley, C; Forrest, G; Soukop, M. Flavone acetic acid : a non linear pharmacokinetic model. Cancer Chemother Pharmacol 22: 114-119. 1988

Goldberg, JA; Kerr, DJ; Willmott, N; McArdle, CS; Murray, T; Hilditch, T Increased uptake of radiolabelled microspheres with angiotensin II in colorectal hepatic metastases. Eur J Surgical Oncol 14: 715. 1988

Kerr, DJ; Harding, M; Amarin, J; Farmer, J; Blackie, RG; Kaye, SB The pharmacokinetics of CHIP in patients with impaired renal function and following intraperitoneal administration.Oncology and Tumour Pharmacotherapy 5 3: 153-158. 1988

Veale, D; Carmichael, J; Cantwell, BMJ; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL A phase I and pharmacokinetic study of didox : A ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72. 1988

Goldberg, JA; Fenner, J; Bessent, RG; Bradnam, MS; McKillop, JH; McKee, RF; McArdle, CS; Kerr, DJ.Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease. Nuclear Med Comm 10: 557-566. 1988

Cummings,-J; Kerr,-D-J; Kaye,-S-B; Smyth,-J-F. Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid

38

and its major human metabolites in plasma and urine. J-Chromatogr. 1988 Sep 23; 431(1): 77-85

Goldberg, JA; Bradnam, MS; Kerr, DJ; Haughton, DM; McKillop, JH;Bessent, RG; Willmott, N; McArdle, CS; George, WD Arterio-venous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate and the effect of angiotensin II.Nuclear Med Comm 8: 1033-1046. 1987

Goldberg, JA; Bradnam, MS; Kerr, DJ; McKillop, JH; Bessent, RG; McArdle, CS; Willmott, N; George, WD Single photon emission computed tomographic studies SPECT of hepatic arterial perfusion scintigraphy HAPS in patients with colo- rectal liver metastases : improved targeting by tumour microspheres with angiotensin II. Nuclear Med Comm 8: 1025-1032. 1987

Cummings, J; Willmott, N; More, I; Kerr, DJ; Lewi, HJ; McKillop, J. Comparitive cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues. Biochemical Pharmacology 36 9: 1521-1526. 1987

Cummings, J; Kerr DJ; Kaye, SB. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987

Kerr, DJ; Kaye, SB; Cassidy, J; Bradley, C; Rankin, EM; Adams, L; Setonoians, A; Young, T; Forrest, G; Soukop, M; Clavel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776-6781. 1987

Cummings, J; Kerr, DJ; Kaye, SB Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987

Cummings, J; Willmott, N; More, I; Kerr, DJ; Gilmour, J; Morrison, JG; Kaye, SB.Comparative cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.Biochem Pharmacol 36 9: 1521-1526. 1987

Kerr, DJ.Microparticulate vehicles as cytotoxic drug carriers. Cancer Drug Delivery 4 1: 55-60. 1987

Kerr, DJ; Kaye, SB.Aspects of cytotoxic drug penetration, with particular reference to anthracyclines.Cancer Chemother Pharmacol 19: 1-5. 1987Kerr, DJ; Kerr, AM; Wheldon, TE; Kaye, SB.In vitro chemosensitivity testing using the multicellular tumour spheroid model. Cancer Drug Delivery 4 2: 124-130. 1987Kerr, DJ; Wheldon, TE; Russell, JG; Maurer, HR; Florence, AT; Halbert, GW; Freshney, RI; Kaye, SB.The effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer, spheroid and clonogenic culture systems. Eur J Cancer Clin. Oncol. 23 9: 1315-1322. 1987Kerr, DJ; Wheldon, TE; Kerr, AM; Freshney, RI; Kaye, SB. The effect of adriamycin and 4'-deoxydoxorubicin on cell survival on human lung tumour cells grown in monolayer and as spheroids. Br J Cancer, 54: 423-429. 1986Kerr, DJ; Kaye, SB; Graham, J; Cassidy, J; Harding, M; Setanoians, A; McGrath, JC; Vezin, WR; Cunningham, D; Forrest, G; Soukop, M. Phase I and pharmacokinetic study of LM985. Cancer Res 46: 3142-3246. 1986Kerr, DJ; Graham, J; Cummings, J; Morrison, JG; Thompson, GG; Brodie, MJ; Kaye, SB The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18: 239-242. 1986

39

Kaye, SB; Cummings, J; Kerr, DJ. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol 21 8: 893-895. 1985Kerr, DJ; Graham, J; Blackie, RG; Cunningham, D; Kaye, SB. The relationship between steady-state plasma levels of metoclopramide and control of cis-platinum induced emesis. Br J Pharmacol 20: 426-427. 1985Kerr, DJ; Kerr, AM; Freshney, I; Kaye, SB. Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol 35 16: 2817-2823. 1985

Kaye,S.B; Cummings,J; Kerr,D.J. How much does liver disease affect the pharmacokinetics of adriamycin? Eur.J.Cancer.Clin.Oncol. 1985 Aug; 21(8): 893-5

Section 3: Gene Therapy

Akita N, Maruta F, Seymour L, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J and Miyagawa S. Identification of oligopeptides binding to peritoneal tumours of gastric cancer. Cancer Science. Vol 97 (1) 1075-1081. 2006

Palmer DH, Chen MJ, Searle PF, Kerr DJ, Young LS. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Ther. 2005 Aug;12(15):1187-97.

Ming-Jen Chen, Nicola K. Green, Gary M. Reynolds, Joanne R. Flavell, Vivien Mautner, David J. Kerr, Lawrence S. Young, Peter F. Searle. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Therapy. 1-11. 2004

Palmer, D H, Mautner V, Mirza D, Oliff S, Gerristen W, Van Der Sijp J R, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill Simon, Harris PA, Searle PF, Young LW, James ND and Kerr DJ. Virus-Directed Enzyme Prodrug Therapy: Intratumoural Administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. Journal of Clinical Oncology. 22: 1546-1552, 2004.

Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, Young LS, Searle PF.Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 2004 Jul;11(14):1126-36.

Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6.

Palmer Green NK, Kerr DJ, Mautner V, Harris PA, Searle PF. The nitroreductase/CB1954 enzyme-prodrug system Methods Mol Med. 2004;90:459-77

Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. Int J Cancer. 2003; 104(1): 104-12.

Palmer DH, Chen MJ, Kerr DJ. Taking Gene Therapy into the Clinic. Journal of Biomedicine and Biotechnology. 2003; 71-77.

Kerr, DJ, Seymour, LW, & Maruta. Gene Therapy for colorectal cancer. Expert Opinion Biol. (2003) 3 (5): 779-788

40

Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003) 3 615-622.

Palmer D H, Milner A E, Kerr D J and Young L S. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductaseCB1954, and identification of synergism with 5-fluorouracil. British Journal of Cancer (September 2003), Volume 89, Number 5, Pages 944-950

Knox RJ, Burke PJ, Chen S and Kerr DJ. CB 1954: From the Walker Tumor to NQO2 and VDEPT. Current Pharmaceutical Design, (2003), 9: 2091-2104

Palmer DH, Milner AE, Kerr DJ, Young LS. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.Br J Cancer. 2003 Sep 1;89(5):944-50.

Kerr DJ, Seymour LW, Maruta F. Gene therapy for colorectal cancer. Expert Opin Biol Ther. 2003 Aug;3(5):779-88.

Maruta F, Parker AL, Fisher KD, Murray PG, Kerr DJ, Seymour LW. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target. 2003 Jan;11(1):53-9.

Maruta,F; Parker,A.L; Fisher,K.D; Hallissey,M.T; Ismail,T; Rowlands,D.C; Chandler,L.A; Kerr,D.J; Seymour,L.W. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer-Gene-Ther. 2002 Jun; 9(6): 543-52

Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Current Opinion in Molecular Therapeutics. 4(5): 423-434 (2002).

Chen, M.J., Chung-Faye, G.A., Searle, P.F., Young, L.S., and Kerr, D.J. (2001). Gene Therapy for colorectal cancer: therapeutic potential. BioDrugs 15, 357-67.

Chung-Faye, G., Palmer, D., Anderson, D., Baddeley, J., Hussain, S, Murray, P.I., Searle, P., Seymour, L., Harris, P.A., Ferry, D., And Kerr, D.J. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7, 2662-8.

Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF*, Kerr DJ. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.. Gene Ther 2001;8(20):1547-54

Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther 2001;3(2):233-40

Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med Today, 6: 82-7 (2000)

Djjeha, A.H., Hulme, A., Mountain, A., Young, L.S., Searle, P.F., Kerr, D.J., and Wrighton, C.M. (2000). Expression E.coli B nitroreductase in established human tumor xenografts in mice results in antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Therapy 7, 721 –731.

41

Weedon,S.J; Green,N.K; McNeish,I.A; Gilligan,M.G; Mautner,V; Wrighton,C.J; Mountain, A; Young,L.S; Kerr,D.J; Searle,P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int-J-Cancer. 2000 Jun 15; 86(6): 848-54

Green, N.K., Weedon, S.J., McNeish, I.A., Mautner, V., Young, L.S., Kerr, D.J., and Searle, P.F. (1999). Gene Therapy for cancer: In vivo killing of tumour cells expressing E-coli nitroreductase following administration of the prodrug CB1954. Gene Therapy 6, 33.

Murray, P.G.,Billingham, L.J., Hassan, H.T., Flavell, J.R., Nelson, P.N., Scott, K., Reynolds, G., Constandinou, C.M., Kerr, D.J., Devey, E.C., Crocker, J., and Young, L.S. (1999). Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin’s disease. Blood 94, 442-447.

Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Design, 14, 461-472 (1999)

Traunecker, H.C., Stevens, M.C.G., Kerr, D.J., and Ferry, D.R (1999). The acridonecarboxamide GF120918 potently reverses P-glycoprotein – mediated resistancein human sarcoma MES-Dx5 cells. British Journal of Cancer 81, 942-951.

Searle, P.F., Weedon, S.J., McNeish, I.A., Gilligan, M.G., Ford, M.J., Friedlos, F., Springer, C.J., Young, L.S., and Kerr, D.J. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E-coli nitroreductase gene. Advances in Experimental Medicine and Biology 451, 107-113. (1998).

Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P and Young LS. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Therapy 5, 965-974 (1998)

Green NK, Gillian MG, Kerr DJ, Searle PF, Young LS. Gene therapy for cancer: prospects for the treatment of lung tumours. Molecular Biology of the Lung, Vol. 2, No 10: 183-201 (1998)

McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, and Searle PF. Virus directed enzyme prodrug therapy for ovarian and pancreatric cancer using retrovirally delivered E. Coli nitroreductase and CB1954. Gene Therapy 1998; 5.1061-9.

McNeish IA, Gilligan MG, Green NK, Roberts SM, Kerr DJ, Friedlos F, Springer CJ, and Searle PF. Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer 1998; 78.155-6.

Herod, JJO; Eliopoulos, AG; Warwick, J; Niedobitek, G; Young, LS; Kerr, DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184. (1996)

Thompson, AM; Steel, CM; Foster, ME; Kerr, D; Paterson, D; Deane, D; Hawkins, RA; Carter, DC; Evans, HJ Gene expression in oestrogen-dependant human breast cancer xenograft tumours. Br J Cancer 62: 78-84. 1990

42

43

General Medicine:

Kerr DJ and Midgley,R: Can we treat cancer for a dollar a day. New England Journal of Medicine, 363:801-803, 2010

Kerr DJ and Scott M. British Lessons on Health Care Reform. Perspective, New England Journal of Medicine. 2009 Sep 24;361(13):e21.

Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea RW, Shepherd S, Stanley A, Sweeney A, Ilde J Wheatley K, on behalf of the WARP Collaborative Group, Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. Feb 2009, 373, 567-574.

Lingwood R, Boyle P, Milburn A, Ngoma T, Arbuthnott J, McCaffrey R, Kerr S and Kerr D. The challenge of cancer control in Africa. Nature Reviews Cancer. 2008, Vol 8: 298-403

Mager, S R, Oomen MHA, Morente MM, Ratcliffe C, Knox K, Kerr DJ, Pezzella F, Riegman PHJ. Standard operating procedure for the collection of fresh frozen tissue samples. European Journal of Cancer. 43: 828-834, 2007.

Kerr F and Kerr DJ. Do we bear any moral responsibility to improving cancer care in Africa? Annals of Oncology. 17: 1730-1731, 2006

Khayat D, Kerr DJ. Opinion: Science and Society: A new model for cancer research in France. Nature Reviews Cancer. 645-651, 2006.

Ref: Cowley AR, Davis J, Dilworth JR, Donnelly PS, Dobson R, Nightingale A, Peach JM, Shore B, Kerr DJ, Seymour L. Fluorescence studies of the intra-cellular distribution of zinc bis (thiosemicarbazone) complexes in human cancer cells. Chem Commun, 845-847, 2005.

Cowley A R., Davis J, Dilworth J, Donnelly P, Dobson R, Nightingale A, Peach J M., Shore B, Kerr D and Seymour L. Contribution of academic research to discovery and development of medicines: current status and future opportunities. European Journal of Pharmaceutical Sciences. 24: 245-252. 2005. .

Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kasler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet. 2005 Jun 11-17;365(9476):1990-2

Couvreur P, Barguer D, Crommelin DJ, Duchene D, Engels JW, Kerr DJ, Krogsgaard-Larsen P, Meijer DK, Paoletti R, Wagner E; EUFEPS. EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities. Eur J Pharm Sci. 2005 Feb;24(2-3):245-52.

Knox K and Kerr DJ. Establishing a national tissue bank for surgically harvested cancer tissue. British Journal of Surgery. 91: 134-136, 2004.

Kerr DJ and Ratcliffe C. Improving service delivery through an integrated approach to translational cancer research. Eur Jour of Surgical Oncology. Vol 30, 61-63, 2004.

44

Kerr D J, Khayat D. The Entente Cordiale – natural and necessary. Annals of Oncology. 15: 1581, 2004

Kerr DJ. NTRAC pioneering a virtual model. The Lancet Oncology. 4:7: 393. 2003

Bevan H, Gowland B, Penny J, Berwich D, Kerr D. Redesigning Cancer Care. 2002. Brit Med Journal. 324:164-166

Spurgeon, P., Barwell, F., and Kerr, D. (2000). Waiting times for cancer patients in England after general practitioners’ referrals: retrospective national survey. British Medical Journal 320, 838-839.

Kerr; D.J. A national cancer plan for the UK. Ann-Oncol. 2000 Dec; 11(12): 1511-2

Stone, P; Richardson,A; Ream,E; Smith,A.G; Kerr,D.J; Kearney,N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000 Aug; 11(8): 971-5

oung A, Kerr DJ. Genetic and immunological therapy for cancer. J R Soc. Med, 93: 10-14 (2000)

Kerr DJ. World summit against cancer for the new millennium the Charter of Paris. Annals of Oncology, 11: 1-2 (2000)

Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffman W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornbergery U, Trunet PF. On behalf of the Letrozole International Trials Group. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Onc. 16, 2 :453-461 (1998).

Green S, Miles R, Kerr D. Improving delivery of cancer services – oncology site specialisation. Health Trends, Vol 30, 3: 80-85 (1998)

Mackean MJ, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, Cassidy J. A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. British Journal of Cancer, 78 (12): 1620-1623 (1998)

Kerr, DJ; Griffiths, R and Edwards B Delivering cancer care: a model for the West Midlands. Brit. J. Cancer, 74: 667-669 (1996)

Hughes, MJ; Kerr, DJ; Cassidy, J; Soukop, M; McGregor, K; Blackburn, N; Yosef, H; Kaye, SB.A pilot study of combination therapy with interferon-a-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Annals of Oncology 7: 208-210 (1996)

Baban, DF; Murray, JA; Earl, HM; Kerr, DJ: Seymour, LW Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia. Int J Oncol 8 1: 29-34 (1996)

Herod, JJO; Kerr, DJ, Luesley, DM. Mechanisms of resistance to platinum chemotherapeutic agents. Contemp Rev Obstet Gynaecol 7: 25-28 (1995)

Miles, R; Kerr, DJ The Calman Report on Cancer Services. Current Obstetrics & Gynaecology 5 4 (1995)

45

De Takats, PG; Dunn, JA; Kerr, DJ; Morrison, JM Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse. Cancer Treat Rev 19b: 11-19. (1993)

Franchesci, S; Boyle, P; La Vecchia, C; Burt, AD; Kerr, DJ; MacFarlane, GJThe epidemiology of thyroid cancer. Critical Reviews in Oncogenesis 41: 25-52 (1993)

Godden, J; Porteous, C; George, WD; Kerr, DJ.Bioassay of Transforming Growth factor-b activity in acidic protein extracts from primary breast cancer specimens. Anticancer Res 13: 427-432 (1993)

Godden, J; Leake, R; Kerr, DJ. The response of breast cancer cells to steroid and peptide growth factors. Anticancer Res. 12: 1683-1688. 1992

Kerr, DJ.Factors that make cancers grow. Science and Public Affairs: 31-36. 1992

Russell, J; Khan, MZ; Kerr, DJ; Spandidos, DA. The effect of transfection with the oncogenes H-ras, c-myc on the radiosensitivity of a mink epithelial cell line. Radiation Research 130: 113-116. 1992

Symonds, RP; Habeshaw, T; Kerr, DJ; Paul, J; Darling, A; Burnett, RA; Sotsiou, F; Linardopoulos, S; Spandidos, DA. No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of cervix. Eur J Cancer 28 10: 1615-1617. 1992

Smart, HE; Canney, P; Kaye, SB; Kerr, DJ. Myelofibrosis associated with seminoma. Clinical Oncology 4: 132. 1992

Knowles, S; Smart, HE; Al-Dawoud, D; Kerr, DJ. Small bowel fistula secondary to endarteritis obliterans complicating chemotherapy for small bowel lymphoma. Brit J Radiology 65: 349-350. 1992

Khan, MZ; Spandidos, DA; Kerr, DJ; McNichol, AM; Lang, JC; de Ridder, L; Freshney, RI. Oncogene transfection of mink lung cells : effect on growth characteristics in vitro and in vivo. Anticancer Res. 11: 1343-1348. 1991

Bissett, D; Kunkeler, L; Zwanenburg, I; Paul, J; Gray, C; Swan, IRC; Kerr, DJ Long-term sequalae of treatment for testicular germ cell tumours. Br J Cancer 62: 655-659. 1990

Leake, R; Kerr, D; Rinaldi, F Steroid hormones and growth factors in breast cancer. Annals NY Acad Sci : 236-241. 1990

Cunningham, D; Bradlay, CJ; Forrest, GJ; Hutcheon, AW; Adams, L; Sneddon, M;Harding, M; Kerr, DJ; Soukop, M; Kaye, SB. A randomised trial of oral nabilone and prochlorperazine compared to intravenous metaclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.Eur J Cancer Clin Oncol 24 4: 685-689. 1988

Graham, J; Harding, M; Mill, L; Kerr, DJ; Rankin, E; Calman, KC; Kaye, SB Results of treatment of non-seminomatous germ cell tumours : 122 consecutive cases in the West of Scotland 1981-1985. Brit J Cancer 57 2: 182-185. 1988

James, G; Kerr, DJ; McLelland, A; Davies, DL. General peripheral nerve dysfunction in acromegaly: a study by conventional and novel neurophysiological techniques. Neurology, Neurosurgery and Psychiatry 50: 886-894. 1987

Kerr, DJ; Halberg, F; Sothern, R; Singh, VH; Alexander, WD. Chronobiologic quantification of thyroid hormone rhythms. Chimioterapia XII: 526-528. 1987

46

Kerr, DJ; Singh, VK; Alexander, WD; Beastall, GH. The effect of low dose nocturnal dopamine infusion on the circadian rhythm of TSH. Clinical Science 72: 737-741. 1987

Tumours of the diffuse endocrine system Kerr, DJ; Anderson, JR; Burt, AD.Europ J Surg Oncol 13: 189-195. 1987

Kerr, DJ; Burt, AD; Holloway, C; Beastall, G The effect of 5-fluorouracil on rat adrenal function. Medical Oncology and Tumour Pharmaco-Therapy 3 2: 101-104. 1986

Kerr, DJ; Singh, VK; McConnell, N; Tsakiris, D; Junor, B. Thyroid function and dialysate hormone loss in haemodialysis and chronic ambulatory peritoneal dialysis patients. Nephron 43: 164-169. 1986

Kerr, DJ; Burt, AD; Boyle, P; MacFarlane, GJ; Storer, AM; Brewin, TB. Prognostic factors in thyroid cancer. Brit J Cancer 54: 475-482. 1986

Kerr, DJ; Singh, VK; Alexander, WD; Sothern, RB; Halberg, I. Chronobiologic quantification of nocturnal low dose dopamine effect on circadian rhythms of thyroid related hormones and prolactin. Chronobiologia Vol XIII 3: 245-248. 1986

Kerr, DJ; Burt, AB; Brewin, TB; Boyle, P. Divergence between mortality and incidence of thyroid cancer.Lancet ii: 1932. 1985

Boyle, P; Burt, D; Kerr, DJ.The geographical pathology of thyroid cancer. Technical Report, 2692. Dana Faber Cancer Institute, Harvard University. 1985

Kerr, DJ; McAlpine, I; Dagg, JH. Pseudohyperkalaemia. Lesson of the Week, British Medical Journal, September, p890. 1985

Burt, AB; Kerr, DJ; Boyle, P; Brown, IL. Lymphoid and epithelial markers in small cell anaplastic thyroid tumours. J.Clin.Pathol. 1985 Aug; 38(8): 893-6

Alexander, WD; Kerr, DJ; Ferguson, MM.First line test of thyroid function.Lancet ii: 647. 1984

Kerr, DJ; Alexander, WD.Is the TRH test usually unnecessary? Lancet ii: 1162. 1984

Kerr, DJ; Elliot, IIL; Hillis, WS Epileptiform seizures and electroencephalographic abnormalities as manifestations of digoxin toxicity. Brit Med Journal 284: 162. 1982

47

PUBLISHED BOOK CHAPTERS

Midgley RS, Al-Salama H, Merrie A, Mortensen N and Kerr DJ. “Colorectal cancer: a multidisciplinary approach”. Textbook of Clinical Gastroenterology and Hepatology. In Press. 2009

Midgley RS, Kerr DJ “Systemic adjuvant therapy of colon cancer” in“Colorectal Cancer” Ed. Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK. (1997)

Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in Surgery” 21.Churchill Livingstone

"Chemoembolism in Cancer Therapy". D J Kerr and S B Kaye in Critical Reviews in Cancer, Ed. S D Brack, p19-39, 8 1, 1991.

"Drug Metabolism and Cancer". M A Graham, R Riley and D J Kerr. Pharmac. Ther. Vol. 51, p275-289, 1991. Ed. M J Brodie. Pergamon Press plc.

"The Effect of Angiotensin II on Tumour Blood Flow and the Delivery of Microparticulate Cytotoxic Drugs". D J Kerr, J A Goldberg, J R Anderson, N Willmott, A T Whateley, C S McArdle and J McKillop. Angiogenesis p339-345. Ed: R Steiner, PB Weisz and R Langer. Birkhauser Verby, 1992.

Graham, MA; Kerr, DJ; Workman, P.Absorption and distribution of anti-cancer drugs. In Florence AT; Salole, EG eds. Pharmaceutical aspects of cancer chemotherapy. Oxford: Butterworth-Heinemann Ltd, pp 1-26. (1993)

"The clinical evaluation of novel chemotherapeutic agents". Poole, CJ; Kerr, DJ in New Molecular targets for cancer chemotherapy. Editors Kerr, Workman, P. CRC Press : 195-212, 1994.

"P-glycoprotein, a transporter with allosterically coupled drug-acceptor sites as a target for rational drug design". Ferry, DR; Kerr, DJ in New molecular targets for chemotherapy. Editors: Kerr, DJ; Workman, P. CRC Press, pp 177-193 (1994)

“Systemic Therapy of colorectal cancer” Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) in “Colorectal Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.

“Principles of pharmacokinetics”. Gouyette, A; Kerr, DJ. In Peckham, Pinedo and Veronesi eds Oxford Textbook of Oncology, Oxford Press, Vol 1, Sect 4.34: 852-864 (1995)

“New and miscellaneous anticancer drugs: future developments in drug design”. Kerr, DJ; Kaye, SB. In Peckham, Pinedo & Veronesi eds. Oxford Textbook of Oncology 1.Oxford Press, pp 578-585 (1995)

"Principles Pharmacokinetique d'Agents Cytotoxique. A Gouyette and D J Kerr in Oncologie. Ed T.Tursz, Presse d’Or 1995.

"Gene-transfer therapy and pancreatic cancer". Searle,PF; Green, NK; Young, LS; Kerr, DJ; Neoptolemos, JP. in Pancreatic Cancer; Molecular and clinical advances chapter 16: 214-223. Editors: Neoptolemos, JP and Lemoine,NR. 1995

"Adjuvant chemotherapy and immunotherapy". DJ Kerr in Colorectal Cancer Chapter 10 pages 151-158. Ed: N S Williams. 1995

48

Morrison, J and Kerr D. Virus-directed suicide gene therapy. Cancer Therapy Molecular Targets in Tumor-host Interactions. Editor: George F Weber. Chapter 16: 363-389. 2005

Nicum S, Midgley RS, Kerr DJ (2004) Chemotherapy and Radiotherapy for Colorectal Cancer. Recent Advances in Coloproctology-Volume 2

Midgley RS, Merrie A, Mortensen N, Kerr DJ (2004) Multi-disciplinary Care of Colorectal Cancer. In Gastroenterology and Hepatology: The Modern Clinicians Guide. Ed Weinstein W, Hawkey CJ and Bosch J. Elsevier Science

Midgley RS (2002) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Revised edition. Ed. Rougier Ph., Kemeny N, Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK

Midgley RS, Young AM, Ferry D, Kerr DJ, (2000) “Systemic Therapy of colorectal cancer” in “Colorectal Cancer” Ed. McArdle C, Kerr DJ, Boyle P. Publ. ISIS Medical Media Ltd,UK.

Midgley RS, Kerr DJ (2000) Is adjuvant chemotherapy for colorectal cancer worthwhile? In: Challenges in colorectal cancer. Ed Scholefield J. Publ. Blackwell Science,UK. Chapter 11:149-165

Midgley RS, Kerr DJ (1998) “Adjuvant chemotherapy for colorectal cancer” in “Recent Advances in Surgery” 21.Churchill Livingstone

Midgley RS, Kerr DJ (1997) “Systemic adjuvant therapy of colon cancer” in “Colorectal Cancer” Ed. Rougier Ph., Bleiberg H, Wilke HJ. Publ. Martin Dunitz Ltd UK.

"Advances in Cancer Research" D J Kerr. Chapter 16, p314-325 in Surgical Oncology. Ed. C S McArdle. Publishers, Butterworth's Ltd.

"Adjuvant treatment of bowel cancer". DJ Kerr and RS Midgley, In: "Surgical Treatment of Colorectal Cancer". Editor Mansell

Textbook of Clinical GI/Hepato. “Colorectal cancer: a multidisciplinary approach chapter”. Midgley RS, Al-Salama HM, Merrie A, Mortensen N and Kerr D J. In press

49

EDITED BOOKS

"New Molecular Targets for Cancer Chemotherapy". Editors DJ Kerr, P Workman, CRC Press 1994.

"Regional Chemotherapy : Principles and Practice". Editors DJ Kerr, CS McArdle. Harwood Academic Publishers 1998.

"Clinical Textbook of colorectal Cancer". Editors DJ Kerr, CS McARdle and P. Boyle. ISIS Academic Publishers 2000.

"ABC of Colorectal Cancer", British Medical Journal Book Series, Editors DJ Kerr, AM Young and R Hobbs, 2001.

“Anticancer Therapeutic Development: from laboratory bench to bedside” – Editors B Baguley and D J Kerr, 2001

“Advances in Colorectal Cancer” Eds Kerr DJ, Bodmer WF, McArdle CS and Pignatelli M. British Medical Bulletin, 64, 2002, Oxford University Press

“Cancer biotherapy an introductory guide”. Eds, Young, Rowett, Kerr. Oxford University Press. 2006.

“Gastrointestinal Oncology: Evidence and Analysis”. Eds, McCulloch, Karpeh, Kerr, Ajani. Informa Healthcare. 2007

“Textbook of Gastrointestinal Cancer”. Eds, Jankowski, Kerr, Fong, Blackwells Publishing. 2008

“Oncology Drugs Handbook”, Oxford University Press, in preparation

“Oxford Textbook of Oncology”, Oxford University Press, in preparation

JOURNAL EDITORIAL BOARDS

Annals of Oncology – Editor in Chief (1998 – 2006) Nature Clinical Cancer Reviews Japanese Journal of Clinical Oncology Seminars in Oncology Molecular Oncology Chinese Clinical Oncology

50